Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ACUTAAS.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ACUTAAS.BO and 80,000+ other tickers.
See exactly how ACUTAAS.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ACUTAAS.BO and 80,000+ other tickers.
Headquartered in Surat, India, Acutaas Chemicals Limited, founded in 2004, operates internationally in the research, development, manufacturing, and distribution of pharmaceutical intermediates. These essential chemical building blocks are vital for both regulated and generic active pharmaceutical ingredients (APIs), serving a broad spectrum of medical uses, including treatments for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant conditions. Beyond its pharmaceutical focus, the firm also produces a varied portfolio of…
No recent news available.